Dermatology Department, Univeristy Hospital ¨Dr. José Eleuterio González¨, Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Dermatol Ther. 2020 Nov;33(6):e14267. doi: 10.1111/dth.14267. Epub 2020 Sep 28.
Androgenetic alopecia (AGA) is an androgen-dependent hereditary trait resulting in hair miniaturization. It is the most common type of alopecia in men and women. During the last years, multiple treatment modalities have been studied, but only topical minoxidil and finasteride have been approved by the US Food and Drug Administration. Microneedling (MN) is a minimally invasive technique that induces collagen formation, as well as growth factors production and neovascularization. Even though not many studies of MN in alopecia have been performed, it remains a favorable treatment modality; however, no standardized protocol for MN in hair loss has been proposed yet. Current evidence is not sufficient to allow a direct comparison with other therapies, but it shows promises to increase hair density, thickness, and quality of hair, especially when combined with other treatments or when used as a drug delivery system. This article aims to summarize the available literature regarding the use of MN alone or associated with other therapies for the treatment of androgenetic alopecia.
雄激素性脱发(AGA)是一种雄激素依赖性遗传性特征,导致毛发微小化。它是男性和女性最常见的脱发类型。在过去的几年中,已经研究了多种治疗方法,但只有局部米诺地尔和非那雄胺获得了美国食品和药物管理局的批准。微针(MN)是一种微创技术,可诱导胶原蛋白形成,以及生长因子的产生和新血管生成。尽管在脱发的 MN 研究并不多,但它仍然是一种有利的治疗方式;然而,目前还没有提出针对脱发的 MN 的标准化方案。目前的证据还不足以与其他疗法进行直接比较,但它显示出增加头发密度、厚度和头发质量的潜力,尤其是与其他治疗方法联合使用或作为药物输送系统使用时。本文旨在总结有关 MN 单独或与其他疗法联合治疗雄激素性脱发的现有文献。